Search Results
Roswell Park Cancer Institute, University of Pittsburgh Cancer Institute, Icahn School of Medicine at Mount Sinai, New Jersey Department of Health, Rutgers Cancer Institute of New Jersey, Elm and Carlton Streets, Buffalo, New York 14263, USA
Search for other papers by Lei Quan in
Google Scholar
PubMed
Search for other papers by Chi-Chen Hong in
Google Scholar
PubMed
Search for other papers by Gary Zirpoli in
Google Scholar
PubMed
Search for other papers by Michelle R Roberts in
Google Scholar
PubMed
Search for other papers by Thaer Khoury in
Google Scholar
PubMed
Search for other papers by Lara E Sucheston-Campbell in
Google Scholar
PubMed
Search for other papers by Dana H Bovbjerg in
Google Scholar
PubMed
Search for other papers by Lina Jandorf in
Google Scholar
PubMed
Search for other papers by Karen Pawlish in
Google Scholar
PubMed
Search for other papers by Gregory Ciupak in
Google Scholar
PubMed
Search for other papers by Warren Davis in
Google Scholar
PubMed
Search for other papers by Elisa V Bandera in
Google Scholar
PubMed
Search for other papers by Christine B Ambrosone in
Google Scholar
PubMed
Search for other papers by Song Yao in
Google Scholar
PubMed
Introduction Breast cancer is a heterogeneous disease. Distribution of tumor characteristics, such as the expression of estrogen receptor (ER), varies by age and ethnic/racial background ( Millikan et al . 2008 , Ambrosone et al . 2014 a
Search for other papers by Benjamin Boyerinas in
Google Scholar
PubMed
Search for other papers by Sun-Mi Park in
Google Scholar
PubMed
Search for other papers by Annika Hau in
Google Scholar
PubMed
Search for other papers by Andrea E Murmann in
Google Scholar
PubMed
Search for other papers by Marcus E Peter in
Google Scholar
PubMed
, differentiation, and apoptosis ( Jovanovic & Hengartner 2006 , Bussing et al . 2008 , Schickel et al . 2008 , Stefani & Slack 2008 ). In respect to their diverse functions, miRs are also known to be involved in many diseases including cancer
Search for other papers by Antoinette S Perry in
Google Scholar
PubMed
Search for other papers by Ruth Foley in
Google Scholar
PubMed
Search for other papers by Karen Woodson in
Google Scholar
PubMed
Search for other papers by Mark Lawler in
Google Scholar
PubMed
Introduction: addressing problems with the clinical management of prostate cancer Prostate cancer (CaP) has a unique set of problems associated with its early detection, diagnosis and treatment that might be aided by the
Search for other papers by Annamaria Biroccio in
Google Scholar
PubMed
Search for other papers by Carlo Leonetti in
Google Scholar
PubMed
Introduction Prostate cancer is the most frequently diagnosed malignancy, apart from skin cancers, in developed countries, and is a leading cause of cancer-related deaths in men ( Feldman & Feldman 2001 ). The risk of prostate
Search for other papers by Raquel Santana da Cruz in
Google Scholar
PubMed
Search for other papers by Johan Clarke in
Google Scholar
PubMed
Search for other papers by Ana Cristina P Curi in
Google Scholar
PubMed
Search for other papers by Aseel Al-Yawar in
Google Scholar
PubMed
Search for other papers by Lu Jin in
Google Scholar
PubMed
Search for other papers by Ali Baird in
Google Scholar
PubMed
Search for other papers by M Idalia Cruz in
Google Scholar
PubMed
Search for other papers by Bhaskar Kallakury in
Google Scholar
PubMed
Search for other papers by Sonia de Assis in
Google Scholar
PubMed
Introduction Pancreatic ductal adenocarcinoma (PDAC) has an overall 5-year survival rate of about 9% ( American Cancer Society 2018 ). This dismal prognosis is due to lack of early detection methods, effective therapies and our poor
Search for other papers by Marianna Volpert in
Google Scholar
PubMed
Prostate Cancer Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia
Search for other papers by Luc Furic in
Google Scholar
PubMed
The School of Biological Sciences, Monash University, Clayton, Victoria, Australia
Search for other papers by Jinghua Hu in
Google Scholar
PubMed
The School of Biological Sciences, Monash University, Clayton, Victoria, Australia
Search for other papers by Anne E O’Connor in
Google Scholar
PubMed
Search for other papers by Richard J Rebello in
Google Scholar
PubMed
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
Computational Cancer Biology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Search for other papers by Shivakumar Keerthikumar in
Google Scholar
PubMed
Department of Physiology, Monash University, Clayton, Victoria, Australia
Search for other papers by Jemma Evans in
Google Scholar
PubMed
The School of Biological Sciences, Monash University, Clayton, Victoria, Australia
Search for other papers by D Jo Merriner in
Google Scholar
PubMed
Search for other papers by John Pedersen in
Google Scholar
PubMed
Prostate Cancer Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia
Search for other papers by Gail P Risbridger in
Google Scholar
PubMed
Search for other papers by Peter McIntyre in
Google Scholar
PubMed
The School of Biological Sciences, Monash University, Clayton, Victoria, Australia
Search for other papers by Moira K O’Bryan in
Google Scholar
PubMed
Introduction Prostate cancer is the most common male cancer in Western societies and the third most common cause of cancer-related mortality ( Jemal et al. 2011 ). Localised prostate cancer is well managed clinically with a 5-year survival
Cancer Prevention and Control Program, Department of Family and Preventive Medicine, Department of Public Health Sciences, Division of Research, Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California 92093-0628, USA
Search for other papers by Wael K Al-Delaimy in
Google Scholar
PubMed
Search for other papers by Shirley W Flatt in
Google Scholar
PubMed
Search for other papers by Loki Natarajan in
Google Scholar
PubMed
Search for other papers by Gail A Laughlin in
Google Scholar
PubMed
Search for other papers by Cheryl L Rock in
Google Scholar
PubMed
Search for other papers by Ellen B Gold in
Google Scholar
PubMed
Search for other papers by Bette J Caan in
Google Scholar
PubMed
Search for other papers by Barbara A Parker in
Google Scholar
PubMed
Search for other papers by John P Pierce in
Google Scholar
PubMed
Introduction As a result of early screening and detection and better treatment options, the number of breast cancer survivors is increasing ( ACS 2005 ). However, there remains an ongoing risk of recurrence among a large proportion of survivors
Search for other papers by Tanya K Day in
Google Scholar
PubMed
Dame Roma Mitchell Cancer Research Laboratories, School of Paediatrics and Reproductive Health, School of Agriculture, Discipline of Medicine, Hanson Institute, Adelaide Prostate Cancer Research Centre, The University of Adelaide, Adelaide, South Australia, Australia
Search for other papers by Tina Bianco-Miotto in
Google Scholar
PubMed
Introduction Numerous diseases are associated with abnormal hormonal regulation including breast and prostate cancers. Breast cancer is a heterogeneous disease that can be classified in many ways. The most primary classification is by hormone
Search for other papers by Lindsay G Carter in
Google Scholar
PubMed
Search for other papers by John A D'Orazio in
Google Scholar
PubMed
Search for other papers by Kevin J Pearson in
Google Scholar
PubMed
been highly studied for the prevention and treatment of many diseases including cancer. After Jang et al . (1997) found that topical application of resveratrol protected mice from tumorigenesis in a skin cancer model in 1997, a wealth of publications
Search for other papers by Marc T Goodman in
Google Scholar
PubMed
Search for other papers by Galina Lurie in
Google Scholar
PubMed
Search for other papers by Pamela J Thompson in
Google Scholar
PubMed
Search for other papers by Katharine E McDuffie in
Google Scholar
PubMed
Search for other papers by Michael E Carney in
Google Scholar
PubMed
Introduction Although the precise role of steroid hormones in ovarian cancer risk is unclear ( Risch 1998 , Lukanova & Kaaks 2005 ), there is growing evidence for a positive association of hormone replacement therapy with ovarian cancer incidence